Search

Orforglipron

Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.

Baxdrostat

It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].

Calcimycin

Primarily used as a biochemical tool for studying divalent cations in biological systems, Calcimycin also exhibits antibiotic activity against gram-positive bacteria and fungi.

Azadirachtin

Azadirachtin is under investigation in clinical trial NCT06617026 (Short-term Outcome of Medical vs. Surgical Management of Chronic Anal Fissure).

Oveporexton

[L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement

Dexfadrostat

Dexfadrostat is under investigation in clinical trial NCT04007406 (DP13 - a Phase II Study in Patients With Primary Aldosteronism).

Milsaperidone

Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo. Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. Similarly, milsaperidone acts ...

AS-602868

AZD0543

AZD0543 is a small molecule drug. AZD0543 is under investigation in clinical trial NCT07824622 (Study of Safety and PK of AZD0543 in Healthy Adults).

ATORM-C

ATORM-C is a biologic drug. ATORM-C is under investigation in clinical trial NCT07822087 (A Phase 1 Study of ATORM-C in Patients With Crohn's Disease).